LAVENDER Phase 3 Trial of Trofinetide Enrolling at New Sites

LAVENDER Phase 3 Trial of Trofinetide Enrolling at New Sites

291387

LAVENDER Phase 3 Trial of Trofinetide Enrolling at New Sites

Acadia Pharmaceuticals is enrolling participants at four new clinical sites in its Phase 3 LAVENDER trial testing trofinetide as a treatment for girls and young women with Rett syndrome. In an online letter to the Rett community, Acadia announced these recent additions: Seattle Children’s Hospital; the University of North Carolina at Chapel Hill; the Kennedy Krieger Institute/ Johns Hopkins School of Medicine, in Baltimore, Maryland; and the Montefiore Medical Center, in New York. The trial (NCT04181723) intends to enroll about…

You must be logged in to read/download the full post.